{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:12:08Z","timestamp":1789503128339,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-031335"],"award-info":[{"award-number":["INV-031335"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UK Medical Research Council  under the MRC\/DFID Concordat Agreement"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HIV-1 drug resistance genotyping is critical to the monitoring of antiretroviral treatment. Data on HIV-1 genotyping success rates of different laboratory specimen types from multiple sources is still scarce.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cross-sectional study, we determined the laboratory genotyping success rates (GSR) and assessed the correlates of genotyping failure of 6837 unpaired dried blood spot (DBS) and plasma specimens. Specimens from multiple studies in a resource-constrained setting were analysed in our laboratory between 2016 and 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We noted an overall GSR of 65.7% and specific overall GSR for DBS and plasma of 49.8% and 85.9% respectively. The correlates of genotyping failure were viral load (VL)\u2009&lt;\u200910,000 copies\/mL (aOR 0.3 95% CI: 0.24\u20130.38; p\u2009&lt;\u20090.0001), lack of viral load testing prior to genotyping (OR 0.85 95% CI: 0.77\u20130.94; p\u2009=\u20090.002), use of DBS specimens (aOR 0.10 95% CI: 0.08\u20130.14; p\u2009&lt;\u20090.0001) and specimens from routine clinical diagnosis (aOR 1.4 95% CI: 1.10\u20131.75; p\u2009=\u20090.005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We report rapidly decreasing HIV-1 genotyping success rates between 2016 and 2019 with increased use of DBS specimens for genotyping and note decreasing median viral loads over the years. We recommend improvement in DBS handling, pre-genotyping viral load testing to screen samples to enhance genotyping success and the development of more sensitive assays with well-designed primers to genotype specimens with low or undetectable viral load, especially in this era where virological suppression rates are rising due to increased antiretroviral therapy roll-out.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07453-9","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T08:03:34Z","timestamp":1652774614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HIV-1 drug resistance genotyping success rates and correlates of Dried-blood spots and plasma specimen genotyping failure in a resource-limited setting"],"prefix":"10.1186","volume":"22","author":[{"given":"Jonah","family":"Omooja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Bugembe","family":"Lule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nannyonjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lunkuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridah","family":"Nassolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella Esther","family":"Nabirye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidah Namagembe","family":"Suubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratius","family":"Ssemwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"7453_CR1","unstructured":"UNAIDS. Fact sheet-Global HIV Statistics [Internet]. 2020 [cited 2020 Oct 11]. Available from: http:\/\/aidsinfo.unaids.org."},{"key":"7453_CR2","unstructured":"Ministry of Health. Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda [Internet]. MOH; 2020. Available from: https:\/\/elearning.idi.co.ug\/pluginfile.php\/5675\/mod_page\/content."},{"key":"7453_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"J Gregson","year":"2016","unstructured":"Gregson J, Tang M, Ndembi N, Hamers RL, Rhee S-Y, Marconi VC, et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565\u201375.","journal-title":"Lancet Infect Dis"},{"key":"7453_CR4","first-page":"3","volume":"17","author":"D Ssemwanga","year":"2015","unstructured":"Ssemwanga D, Lihana RW, Ugoji C, Abimiku A, Nkengasong J, Dakum P, et al. Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Rev. 2015;17:3\u201320.","journal-title":"AIDS Rev"},{"key":"7453_CR5","doi-asserted-by":"crossref","unstructured":"Aves T, Tambe J, Siemieniuk RA, Mbuagbaw L. Antiretroviral resistance testing in HIV\u2010positive people. Cochrane Database Syst Rev [Internet]. 2018 [cited 2020 Oct 12];2018. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6517236\/.","DOI":"10.1002\/14651858.CD006495.pub5"},{"key":"7453_CR6","unstructured":"UNAIDS. Understanding FastTrack Accelerating Action to End the AIDS Epidemic by 2030. 2015."},{"key":"7453_CR7","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. 2021 update. Geneva: World Health Organization; 2021 [cited 2021 Aug 23]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/342899."},{"key":"7453_CR8","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. 2020 [cited 2020 Oct 11]. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"7453_CR9","unstructured":"WHO. HIV Drug Resistance: Surveillance of HIV drug resistance in Adults receiving ART (Acquired HIV drug resistance) [Internet]. 2014. Available from: www.who.int."},{"key":"7453_CR10","unstructured":"The WHO. Surveillance of HIV drug resistance in adukts initiating antiretroviral therapy (Pre-treatment HIV drug resistance) [Internet]. WHO; 2014 [cited 2020 Oct 11]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112802\/9789241507196_eng.pdf;jsessionid=AAC44A20E97B74CF7A52D52829125A02?sequence=1."},{"key":"7453_CR11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1001\/jama.279.24.1984","volume":"279","author":"MS Hirsch","year":"1998","unstructured":"Hirsch MS, Conway B, D\u2019Aquila RT, Johnson VA, Brun-V\u00e9zinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA Am Med Assoc. 1998;279:1984\u201391.","journal-title":"JAMA Am Med Assoc"},{"key":"7453_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/589297","volume":"47","author":"MS Hirsch","year":"2008","unstructured":"Hirsch MS, G\u00fcnthard HF, Schapiro JM, Brun-V\u00e9zinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 Infection: 2008 recommendations of an international AIDS Society\u2013USA Panel. Clin Infect Dis. 2008;47:266\u201385.","journal-title":"Clin Infect Dis"},{"key":"7453_CR13","doi-asserted-by":"crossref","unstructured":"Bbosa N, Ssemwanga D, Nsubuga RN, Salazar-Gonzalez JF, Salazar MG, Nanyonjo M, et al. Phylogeography of HIV-1 suggests that Ugandan fishing communities are a sink for, not a source of, virus from general populations. Sci Rep [Internet]. 2019;9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6355892\/.","DOI":"10.1038\/s41598-018-37458-x"},{"key":"7453_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/COH.0000000000000542","volume":"14","author":"L Abeler-D\u00f6rner","year":"2019","unstructured":"Abeler-D\u00f6rner L, Grabowski MK, Rambaut A, Pillay D, Fraser C. PANGEA-HIV 2: phylogenetics and networks for generalised epidemics in Africa. Curr Opin HIV AIDS. 2019;14:173\u201380.","journal-title":"Curr Opin HIV AIDS"},{"key":"7453_CR15","unstructured":"Stanford HIV drug resistance database. Major HIV-1 Drug Resistance Mutations [Internet]. 2015 [cited 2017 Aug 29]. Available from: https:\/\/hivdb.stanford.edu\/pages\/download\/resistanceMutations_handout.pdf."},{"key":"7453_CR16","unstructured":"World Health Organization. WHO HIVResNet HIV drug resistance Laboratory Operational Framework Second Edition [Internet]. 2021 update. Geneva: World Health Organization; 2021 [cited 2021 Aug 23]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/343175."},{"key":"7453_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/00002030-199110000-00006","volume":"5","author":"S Escaich","year":"1991","unstructured":"Escaich S, Ritter J, Rougier P, Lepot D, Lamelin JP, Sepetjan M, et al. Plasma viraemia as a marker of viral replication in HIV-infected individuals. AIDS. 1991;5:1189\u201394.","journal-title":"AIDS"},{"key":"7453_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jac\/dkp353","volume":"64","author":"A Johannessen","year":"2009","unstructured":"Johannessen A, Tr\u00f8seid M, Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother. 2009;64:1126\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR19","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1097\/QAD.0b013e328331f702","volume":"23","author":"SM Lofgren","year":"2009","unstructured":"Lofgren SM, Morrissey AB, Chevallier CC, Malabeja AI, Edmonds S, Amos B, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote health care facilities. AIDS. 2009;23:2459\u201366.","journal-title":"AIDS"},{"key":"7453_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1128\/JCM.03048-12","volume":"51","author":"KN Ouma","year":"2013","unstructured":"Ouma KN, Basavaraju SV, Okonji JA, Williamson J, Thomas TK, Mills LA, et al. Evaluation of quantification of HIV-1 RNA viral load in plasma and dried blood spots by use of the semiautomated cobas amplicor assay and the fully automated cobas ampliprep\/TaqMan assay, version 2.0, in Kisumu, Kenya. J Clin Microbiol. 2013;51:1208\u201318.","journal-title":"J Clin Microbiol"},{"key":"7453_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/jac\/dkn100","volume":"61","author":"AS Youngpairoj","year":"2008","unstructured":"Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garc\u00eda-Lerma JG. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4\u00b0C. J Antimicrob Chemother. 2008;61:1217\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR22","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1128\/JCM.00544-14","volume":"52","author":"CM Parry","year":"2014","unstructured":"Parry CM, Parkin N, Diallo K, Mwebaza S, Batamwita R, DeVos J, et al. Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. J Clin Microbiol. 2014;52:2868\u201375.","journal-title":"J Clin Microbiol"},{"key":"7453_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jviromet.2015.07.005","volume":"223","author":"AT Salimo","year":"2015","unstructured":"Salimo AT, Ledwaba J, Coovadia A, Abrams EJ, Technau K-G, Kuhn L, et al. The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods. 2015;223:30\u20132.","journal-title":"J Virol Methods"},{"key":"7453_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jvh.12345","volume":"22","author":"J Greenman","year":"2015","unstructured":"Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepatitis. 2015;22:353\u201361.","journal-title":"J Viral Hepatitis"},{"key":"7453_CR25","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1128\/JCM.01004-11","volume":"49","author":"C Ziemniak","year":"2011","unstructured":"Ziemniak C, Mengistu Y, Ruff A, Chen Y-H, Khaki L, Bedri A, et al. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol. 2011;49:4077\u201382.","journal-title":"J Clin Microbiol"},{"key":"7453_CR26","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/jac\/dkq205","volume":"65","author":"M Monleau","year":"2010","unstructured":"Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother. 2010;65:1562\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR27","doi-asserted-by":"publisher","first-page":"e56170","DOI":"10.1371\/journal.pone.0056170","volume":"8","author":"H Ji","year":"2013","unstructured":"Ji H, Li Y, Liang B, Pilon R, MacPherson P, Bergeron M, et al. Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment na\u00efve and experienced patients. PLoS ONE. 2013;8:e56170.","journal-title":"PLoS ONE"},{"key":"7453_CR28","doi-asserted-by":"crossref","unstructured":"Gr\u00fcner N, Stambouli O, Ross RS. Dried blood spots\u2014preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp. 2015;52619.","DOI":"10.3791\/52619"},{"key":"7453_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1093\/jac\/dkab159","volume":"76","author":"C Watera","year":"2021","unstructured":"Watera C, Ssemwanga D, Namayanja G, Asio J, Lutalo T, Namale A, et al. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. J Antimicrob Chemother. 2021;76:2407\u201314.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR30","doi-asserted-by":"publisher","first-page":"e78609","DOI":"10.1371\/journal.pone.0078609","volume":"8","author":"C Kiyaga","year":"2013","unstructured":"Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V, et al. Uganda\u2019s new national laboratory sample transport system: a successful model for improving access to diagnostic services for early infant HIV diagnosis and other programs. PLoS ONE. 2013;8:e78609.","journal-title":"PLoS ONE"},{"key":"7453_CR31","unstructured":"University of Michigan Medical School, Biomedical Research Core facilities. Interpretation of Sequencing Chromatograms | Sanger Sequencing\/Fragment Analysis FAQs [Internet]. U-M Biomedical Research Core Facilities. 2020 [cited 2021 Aug 25]. Available from: https:\/\/brcf.medicine.umich.edu\/cores\/advanced-genomics\/faqs\/sanger-sequencing-faqs\/interpretation-of-sequencing-chromatograms\/."},{"key":"7453_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191411","volume":"13","author":"TM Pollack","year":"2018","unstructured":"Pollack TM, Duong HT, Truong PT, Pham TT, Do CD, Colby D. Sensitivity and specificity of two dried blood spot methods for HIV-1 viral load monitoring among patients in Hanoi, Vietnam. PLoS ONE. 2018;13: e0191411.","journal-title":"PLoS ONE"},{"key":"7453_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145536","volume":"10","author":"P Kaleebu","year":"2015","unstructured":"Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, et al. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in Uganda. PLoS ONE. 2015;10: e0145536.","journal-title":"PLoS ONE"},{"key":"7453_CR34","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1128\/JCM.06689-11","volume":"50","author":"CK Woods","year":"2012","unstructured":"Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50:1936\u201342.","journal-title":"J Clin Microbiol"},{"key":"7453_CR35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30:1312\u20133.","journal-title":"Bioinformatics"},{"key":"7453_CR36","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608\u201318.","journal-title":"Clin Infect Dis"},{"key":"7453_CR37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/jac\/dkz261","volume":"74","author":"J Omooja","year":"2019","unstructured":"Omooja J, Nannyonjo M, Sanyu G, Nabirye SE, Nassolo F, Lunkuse S, et al. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. J Antimicrob Chemother. 2019;74:3021\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR38","doi-asserted-by":"publisher","first-page":"e0203296","DOI":"10.1371\/journal.pone.0203296","volume":"13","author":"G Zhang","year":"2018","unstructured":"Zhang G, DeVos J, Medina-Moreno S, Wagar N, Diallo K, Beard RS, et al. Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings. PLoS ONE. 2018;13:e0203296.","journal-title":"PLoS ONE"},{"key":"7453_CR39","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2352-3018(15)00020-X","volume":"2","author":"L Zhang","year":"2015","unstructured":"Zhang L, Phanuphak N, Henderson K, Nonenoy S, Srikaew S, Shattock AJ, et al. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study. The Lancet HIV. 2015;2:e200\u20137.","journal-title":"The Lancet HIV"},{"key":"7453_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/135965350701200114","volume":"12","author":"S Bertagnolio","year":"2007","unstructured":"Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, Fuentes L, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther. 2007;12:107.","journal-title":"Antivir Ther"},{"key":"7453_CR41","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/jac\/dkz561","volume":"75","author":"D Ssemwanga","year":"2020","unstructured":"Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, et al. Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. J Antimicrob Chemother. 2020;75:1280\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jcv.2007.12.011","volume":"41","author":"R Hallack","year":"2008","unstructured":"Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol. 2008;41:283\u20137.","journal-title":"J Clin Virol"},{"key":"7453_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/jac\/dkq433","volume":"66","author":"A Johannessen","year":"2011","unstructured":"Johannessen A, Garrido C, Zahonero N, Naman E, de Mendoza C. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 genotyping system. J Antimicrob Chemother. 2011;66:260\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"7453_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/240407","volume":"2015","author":"JP Rodriguez-Auad","year":"2015","unstructured":"Rodriguez-Auad JP, Rojas-Montes O, Maldonado-Rodriguez A, Alvarez-Mu\u00f1oz MaT, Mu\u00f1oz O, Torres-Ibarra R, et al. Use of dried plasma spots for HIV-1 viral load determination and drug resistance genotyping in Mexican patients. BioMed Res Int. 2015;2015:1\u20139.","journal-title":"BioMed Res Int"},{"key":"7453_CR45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/cid\/cis015","volume":"54","author":"EK Rottinghaus","year":"2012","unstructured":"Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, DeVos J, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis Oxford Academic. 2012;54:1187\u201395.","journal-title":"Clin Infect Dis Oxford Academic"},{"key":"7453_CR46","doi-asserted-by":"publisher","unstructured":"Dried blood spots for HIV\u20101 drug resistance genotyping in decentralized settings in Senegal\u2014Diouara\u20142014\u2014Journal of Medical Virology\u2014Wiley Online Library [Internet]. [cited 2020 Oct 16]. https:\/\/doi.org\/10.1002\/jmv.23778.","DOI":"10.1002\/jmv.23778"},{"key":"7453_CR47","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1097\/QAD.0b013e3281c618db","volume":"21","author":"S Masciotra","year":"2007","unstructured":"Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS. 2007;21:2503\u201311.","journal-title":"AIDS"},{"key":"7453_CR48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4103\/0255-0857.103759","volume":"30","author":"S David","year":"2012","unstructured":"David S, Sachithanandham J, Jerobin J, Parasuram S, Kannangai R. Comparison of HIV-1 RNA level estimated with plasma and DBS samples: a pilot study from India (South). Indian J Med Microbiol. 2012;30:403\u20136.","journal-title":"Indian J Med Microbiol"},{"key":"7453_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jviromet.2012.02.006","volume":"181","author":"M Vidya","year":"2012","unstructured":"Vidya M, Saravanan S, Rifkin S, Solomon SS, Waldrop G, Mayer KH, et al. Dried blood spots versus plasma for the quantitation of HIV-1 RNA using a real-Time PCR, m2000rt assay. J Virol Methods. 2012;181:177\u201381.","journal-title":"J Virol Methods"},{"key":"7453_CR50","doi-asserted-by":"crossref","unstructured":"Kantor R, Delong A, Schreier L, Reitsma M, Kemboi E, Orido M, et al. HIV second-line failure and drug resistance at high- and low-level viremia in Western Kenya: AIDS. 2018;1.","DOI":"10.1097\/QAD.0000000000001964"},{"key":"7453_CR51","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/ciu019","volume":"58","author":"A Gonzalez-Serna","year":"2014","unstructured":"Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JSG, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58:1165\u201373.","journal-title":"Clin Infect Dis"},{"key":"7453_CR52","first-page":"1","volume":"2017","author":"S Gupta","year":"2017","unstructured":"Gupta S, Taylor T, Patterson A, Liang B, Bullard J, Sandstrom P, et al. A robust PCR protocol for HIV drug resistance testing on low-level viremia samples. Biomed Res Int. 2017;2017:1\u20136.","journal-title":"Biomed Res Int"},{"key":"7453_CR53","doi-asserted-by":"publisher","first-page":"e0173009","DOI":"10.1371\/journal.pone.0173009","volume":"12","author":"PA Minchella","year":"2017","unstructured":"Minchella PA, Chipungu G, Kim AA, Sarr A, Ali H, Mwenda R, et al. Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi. PLoS ONE. 2017;12:e0173009.","journal-title":"PLoS ONE"},{"key":"7453_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005475","volume":"95","author":"P Pannus","year":"2016","unstructured":"Pannus P, Claus M, Gonzalez MMP, Ford N, Fransen K. Sensitivity and specificity of dried blood spots for HIV-1 viral load quantification: a laboratory assessment of 3 commercial assays. Medicine (Baltimore). 2016;95: e5475.","journal-title":"Medicine (Baltimore)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07453-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T08:05:17Z","timestamp":1652774717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07453-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7453"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07453-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is under the HIV Molecular Epidemiology study that was approved by the Uganda Virus Research Institute Ethics committee [UVRI-REC Federal wide Assurance (FWA) No. 00001354] and the Uganda National Council for Science and Technology (UNCST FWA No. 00001293). Participants to all studies analysed were recruited voluntarily and submitted written informed consent. All studies used methods that were compliant with ethical research guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}